{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-011876","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2026-08-04T20:05:36+00:00","discovered_at":"2026-08-04T20:07:00.223737+00:00","generated_at":"2026-08-04T20:07:58.610948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precigen reports Q2 2026 net income of $20.1M; PAPZIMEOS revenue $53.1M, more than double prior quarter","bullets":["PAPZIMEOS net revenue $53.1M in Q2 2026, more than double prior quarter; total revenues $55.0M.","Net income $20.1M ($0.06 basic EPS) vs net loss $26.6M ($0.09 loss) in Q2 2025.","Cash, equivalents, and investments $38.7M as of June 30, 2026; expects cash flow break-even by end of 2026.","FDA granted PAPZIMEOS seven-year market exclusivity; patient hub enrollment over 500 patients.","MAA for PAPZIMEOS under review by EMA; PRGN-2009 pipeline update expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-011876","json":"https://secwatch.observer/filing/0000950103-26-011876.json","markdown":"https://secwatch.observer/filing/0000950103-26-011876.md","text":"https://secwatch.observer/filing/0000950103-26-011876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/0000950103-26-011876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:07:58.610948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}